▼ bearish
Impact
PhasePre-approval biosimilar (351(k)) development — analytical comparability stage; no active Phase 2/3 trial in local data a
Time to marketUnknown — several years at best. The program is still in FDA pathway-alignment (Type 2a meeting held Jan 2026; Type 2b planned 2H26); a BLA has not been filed and five-year milestone warrants are tied to Phase 3 trial initiation, so US approval is likely late-2020s or later if the biosimilar path succeeds.
ABP-450 botulinum toxin type a (biosimilar candidate to onabotulinumtoxinA) Updated Aug 17
What to watch
Treat the ~$6.70 two-analyst price target as a stale artifact set before the July 2026 re-IPO dilution (stock trades ~$0.26, near its 52-week low of $0.222). Watch the FDA Type 2b meeting in 2H26, its minutes trigger expiry of the two-year milestone warrants and could unlock up to $34M in additional gross proceeds, a potential double-edged catalyst: capital in, but at heavy dilution. Also monitor NYSE American compliance status after the August 3, 2026 deadline to regain listing standards.
Bull case
- Positive FDA engagement: Type 2a meeting held Jan 21, 2026 to align the analytical pathway, with 'positive FDA feedback and analytical similarity to BOTOX' highlighted in the FY2025 results and a Type 2b meeting planned for 2H26 (FDA catalyst rows + Q1 2026 earnings report).
- Comparability data presented at the American Headache Society meeting June 4, 2026 support the biosimilar thesis of full-label US market entry.
- Analyst consensus is heavily bullish: 6 Buy + 2 Strong Buy vs 1 Hold (Aug 2026), with a 2-analyst mean price target of $6.70 observed Aug 14, 2026 (implied upside ~2,522% vs $0.27, treat as stale pre-dilution targets).
Bear case
- ABP-450 is the company's sole candidate and it is pre-revenue: FY2025 net loss of $39.2M, year-end cash of $3.0M, and a stockholders' deficit of ~$55M (FY2025 report, Mar 30, 2026).
- Massively dilutive July 15, 2026 offering: ~17.85M shares, 24.84M pre-funded warrants and 85.38M milestone warrants at ~$0.32/unit; gross proceeds ~$13.75M vs a ~$9M pre-offering market cap, with fully diluted share count potentially rising over 10x (8-K analysis, impact score 8).
- NYSE American non-compliance: 8-K of Apr 3, 2026 disclosed a stockholders'-deficit listing violation (~$55M), with a deadline to regain compliance by Aug 3, 2026 or face delisting; delisting/reverse-split risk flagged repeatedly.